Australia’s Therapeutic Goods Administration (TGA) may reschedule psilocybin and MDMA to increase access to psychedelic medicine.
After assessing several studies, the TGA recognized that the two drugs have promising therapeutic potential for treating anxiety and depression.
The substances are currently classified as Schedule 9, or “prohibited substances”, creating a barriers for conducting clinical research. The TGA is considering changing the classification to Schedule 8, or “controlled substances” (the same as THC) to allow controlled use in clinical settings. The verdict will be announced in the first week of December after an advisory committee meeting!